All In Biotech

Drug Trial Radar · NCT01335399

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 748 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

748

Actual

Start

Aug 4, 2011

Primary completion

Oct 1, 2019

Study completion Sep 3, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Apr 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)

Conditions

  • Multiple Myeloma

Interventions

  • LenalidomideDrug

    Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • DexamethasoneDrug

    Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • DexamethasoneDrug

    Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • DexamethasoneDrug

    Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • DexamethasoneDrug

    Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • Elotuzumab (BMS-901608; HuLuc63)Biological

    Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • Elotuzumab (BMS-901608; HuLuc63)Biological

    Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)

Locations

235 sites in 20 countries. Site status is shown where the registry gives one.

  • Local Institution - 1628

    Birmingham, Alabama

  • Local Institution - 7619

    Mobile, Alabama

  • Local Institution - 7618

    Mobile, Alabama

  • Local Institution - 7617

    Chandler, Arizona

  • Local Institution - 1644

    Tucson, Arizona

  • Local Institution - 1618

    Bakersfield, California

  • Local Institution - 1602

    Berkeley, California

  • Local Institution - 1636

    Corona, California

  • Local Institution - 1668

    Corona, California

  • Local Institution - 1616

    Greenbrae, California

  • Local Institution - 7609

    Long Beach, California

  • Local Institution - 1660

    Los Angeles, California

  • Local Institution - 1673

    Orange, California

  • Local Institution - 1613

    San Diego, California

  • Local Institution - 1621

    New Haven, Connecticut

  • Local Institution - 1612

    Washington D.C., District of Columbia

  • Local Institution - 1682

    Boca Raton, Florida

  • Local Institution - 1617

    Brooksville, Florida

  • Local Institution - 1648

    Fort Myers, Florida

  • Local Institution - 7613

    Hollywood, Florida

  • Local Institution - 1623

    Jacksonville, Florida

  • Local Institution - 1625

    New Port Richey, Florida

  • Local Institution - 1649

    St. Petersburg, Florida

  • Local Institution - 1611

    West Palm Beach, Florida

  • Local Institution - 1630

    Atlanta, Georgia

  • Local Institution - 1684

    Honolulu, Hawaii

  • Local Institution - 1607

    Chicago, Illinois

  • Local Institution - 1635

    Chicago, Illinois

  • Local Institution - 1632

    Maywood, Illinois

  • Local Institution - 7606

    Peoria, Illinois

  • Local Institution - 7610

    Skokie, Illinois

  • Local Institution - 1603

    Urbana, Illinois

  • Local Institution - 7616

    Bloomington, Indiana

  • Local Institution - 7620

    Indianapolis, Indiana

  • Local Institution - 1669

    Indianapolis, Indiana

  • Local Institution - 1656

    Mishawaka, Indiana

  • Local Institution - 1633

    Iowa City, Iowa

  • Local Institution - 1674

    Lexington, Kentucky

  • Local Institution - 1683

    Louisville, Kentucky

  • Local Institution - 1646

    Lafayette, Louisiana

Showing 40 of 235 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.